Northland analyst Carl Byrnes named Sanuwave Health as a 2026 Top Pick with an Outperform rating and $55 price target. The company's UltraMist installed base was up 55% year-over-year ending Q3, notes the analyst, who believes recent CMS PFS/OPPS reimbursement changes for skin substitutes should act as a demand catalyst for UltraMist as physicians seek incremental, procedure-based revenue.
